Project Details
Description
A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction
| Status | Finished |
|---|---|
| Effective start/end date | 5/1/14 → 3/1/20 |
Funding
- NOVARTIS PHARMA AG
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.